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MGMT promoter methylation in malignant gliomas: ready for personalized 
medicine?  
Michael Weller, Roger Stupp, Guido Reifenberger, Alba A. Brandes, Martin J. van den 
Bent, Wolfgang Wick and Monika E. Hegi 
 
ABSTRACT 
The DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) 
antagonizes the genotoxic effects of alkylating agents. MGMT promoter methylation is 
the key mechanism of MGMT gene silencing and predicts a favorable outcome in 
patients with glioblastoma who are exposed to alkylating agent chemotherapy. This 
biomarker is on the verge of entering clinical decision-making and is currently used to 
stratify or even select glioblastoma patients for clinical trials. In other subtypes of glioma, 
such as anaplastic gliomas, the relevance of MGMT promoter methylation might extend 
beyond the prediction of chemosensitivity, and could reflect a distinct molecular profile. 
Here, we review the most commonly used assays for evaluation of MGMT status, outline 
the prerequisites for standardized tests, and evaluate reasons for difficulties in 
reproducibility. We critically discuss the prognostic and predictive value of MGMT 
silencing, reviewing trials in which patients with different types of glioma were treated 
with various chemotherapy schedules, either upfront or at recurrence. Standardization of 
MGMT testing requires comparison of different technologies across laboratories, and 
prospectively validated cut-off values for prognostic or predictive effects. Moreover, 
future clinical trials will need to determine, for each subtype of glioma, the degree to 
which MGMT promoter methylation is predictive or prognostic, and whether testing 
should become routine clinical practice. 
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Key points 
 MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation has 
become the most powerful molecular prognosticator in malignant gliomas 
 MGMT promoter methylation is predictive for response to alkylating agent 
chemotherapy in glioblastoma 
 Methylation-specific PCR is the only validated technique to derive prognostic 
information from determination of the MGMT status 
 The MGMT status has become a parameter for stratification of patients with 
glioma within clinical trials 
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INTRODUCTION  
O6-methylguanine-DNA methyltransferase (MGMT) is a ubiquitous DNA repair enzyme 
that has been highly conserved throughout evolution. MGMT is associated with 
resistance to alkylating agent cancer therapy, and modulation of this enzyme as a 
treatment target has been under investigation for over 2 decades.1,2 MGMT rapidly 
reverses alkylation, including methylation, at the O6 position of guanine by transferring 
the alkyl group to the active site of the enzyme.3 Although O6-alkylguanine is not the 
main lesion induced by alkylating agents, it seems to be the most cytotoxic one. Lack of 
MGMT in the cell allows accumulation of O6-alkylguanine in the DNA, which, subsequent 
to incorrect pairing with thymidine, triggers mismatch repair, thereby inducing DNA 
damage signaling and, eventually, cell death.4,5 In accordance with this postulated 
mechanism, mismatch repair-deficient cells are highly resistant to alkylating agents, 
even in the absence of MGMT. 
In this article, we critically review the prognostic and predictive value of MGMT 
silencing in gliomas, drawing on the results of trials in which various chemotherapy 
schedules were used to treat patients with these tumors. We discuss the assays that are 
most commonly used to evaluate MGMT status, outline the prerequisites for 
standardized tests, and consider possible reasons for difficulties in reproducibility.  
 
THE MGMT GENE AND ITS PROMOTER 
The MGMT gene is located on chromosome 10q26. Its promoter lacks the constitutive 
regulatory elements known as the TATA box and the CAT box, similar to many 
housekeeping genes, and contains a CpG island. CpG islands are genomic regions, 
typically of 300–3000 bp, that contain a high frequency of CG dinucleotides (CpG sites), 
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and are often located in the vicinity of the transcription initiation site. The region required 
for maximal promoter activity lies at the 5’ end of the gene (from bps –953 to +202; 
transcription initiation site +1 bp) and comprises a minimal promoter, an enhancer region 
to which the MGMT enhancer-binding protein (MEBP) binds, and a number of 
transcription factor binding sites, such as those for Sp1 and AP1 (Figure 1). Expression 
levels of MGMT vary considerably between organs, with relatively low levels in the brain 
and the highest levels in the liver. Tumors frequently exhibit higher levels of expression 
than do their tissue of origin.1  
The CpG island is located in the 5’ region of MGMT (bps –552 to +289) and 
includes 97 CpGs (Figure 1), which are usually unmethylated in normal tissues. Methyl-
CpG-binding proteins, such as methyl-CpG-binding protein 2 (MeCP2) and methyl-CpG-
binding domain protein 2 (MBD2), bind to aberrantly methylated sequences, leading to 
alterations of chromatin structure and preventing binding of transcription factors, thereby 
silencing the gene (Figures 1 and 2a).16 Some studies have provided insight into the 
relationship between gene expression and the patterns and localization of dense CpG 
methylation in the MGMT promoter.16,17 Two regions that are prone to high levels of 
methylation have been identified, of which the region comprising the enhancer element 
seems to be more critical for the loss of MGMT gene expression upon methylation, on 
the basis of luciferase reporter assays interrogating different regions of the methylated 
promoter.16,17 Hence, most methylation-specific tests are designed to interrogate this 
region (Figure 2b). 
 
MGMT PROMOTOR METHYLATION IN GLIOMAS  
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The first striking observations on a potential predictive value of MGMT protein levels, as 
determined by immunofluorescence microscopy, in patients with malignant glioma were 
made more than 10 years ago.6,7 Patients with low levels of MGMT seemed to derive 
considerably more benefit from carmustine (BCNU) than those with high levels. 
Similarly, low levels of MGMT protein, as detected by immunohistochemistry, predicted 
prolonged progression-free survival (PFS) in patients with glioma treated upfront with 
temozolomide,8 or prolonged overall survival in patients with newly diagnosed, 
inoperable glioblastoma treated with neoadjuvant temozolomide.9  
Decreased levels of MGMT protein can be attributed to epigenetic silencing 
mediated by MGMT gene promoter methylation, which can be assessed by a simple 
methylation-specific PCR (MSP). A correlation with survival was demonstrated when 
glioma patients were treated with nitrosoureas10 or temozolomide,11 strongly suggesting 
that MGMT promoter methylation assessment could provide a prognostic or predictive 
biomarker for benefit from alkylator-based chemotherapy added to radiotherapy. 
Subsequently, in the randomized European Organisation for Research and Treatment of 
Cancer (EORTC) 26981-22981–National Cancer Institute of Canada (NCIC) CE.3 
trial,12,13 MGMT promoter methylation was shown to predict prolonged PFS specifically 
in patients treated with temozolomide and radiotherapy, consistent with the idea that 
methylation predicts benefit from alkylating agent chemotherapy rather than simply 
being yet another prognostic marker. By contrast, only a slight trend was observed 
towards longer PFS in patients with methylated versus unmethylated tumors who were 
treated with radiotherapy alone.13 This study used a nonquantitative gel-based MSP 
assay and dichotomized patients into methylated and unmethylated groups (45% versus 
55%). Quantitative assays, such as real-time, quantitative PCR (qMSP), suggest that a 
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subgroup of patients with intermediate methylation exists, representing a ‘gray zone’ in 
the test results. This observation could account for the fact that some patients with 
MGMT-methylated tumors seemed to derive no benefit from temozolomide, whereas 
some patients in the unmethylated group did benefit from the treatment. The modest 
effect of temozolomide in patients lacking MGMT promoter methylation has provoked an 
ongoing discussion as to whether MGMT testing should be made mandatory, and 
whether temozolomide should be withheld from patients with tumors that lack MGMT 
promoter methylation.  
The possible predictive value of MGMT promoter methylation specifically for the 
benefit derived from alkylating chemotherapy in glioblastoma patients has recently been 
challenged in patients with anaplastic glioma. A trial by the German Cancer Society’s 
Neuro-Oncology Working Group (NOA-04) showed prolonged PFS and overall survival 
in WHO grade III anaplastic glioma patients with MGMT promoter methylation, 
irrespective of initial treatment with radiotherapy or alkylating agent chemotherapy, 
temozolomide or procarbacin, CCNU and vincristin (PCV).14 Similarly, in the EORTC 
trial 26951 on adjuvant PCV chemotherapy, PFS was prolonged in patients whose 
tumors showed MGMT promoter methylation independent of the administration of 
alkylating agent chemotherapy.15 Since no evidence exists that MGMT is involved in the 
repair of radiation-induced DNA damage, other, as yet unknown, genetic alterations 
associated with MGMT promoter methylation and predictive for sensitivity to irradiation 
could be operating in MGMT-methylated anaplastic gliomas. These findings raise the 
question of whether MGMT promoter methylation is merely an epiphenomenon of other 
important predictive and prognostic markers, and they also underline the idea that grade 
III and grade IV gliomas need to be studied as separate entities. 
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Assessing MGMT status in tumor tissue  
The potential clinical utility of MGMT status as a biomarker in gliomas has led to an 
ongoing debate regarding how this status should be assessed—by promoter methylation 
analysis, at the level of mRNA or protein expression, or by enzyme activity—and which 
specific procedure is best suited for routine clinical applications.18,19 A biomarker test for 
MGMT status needs to be standardized, suitable for high-throughput analyses and 
reproducible in independent laboratories, and must have a clinically relevant cut-off 
point. The test should allow prospective patient selection and individualized therapy, 
thereby pursuing the strategy of personalized medicine for patients with brain tumors. 
 
Enzyme activity 
The enzymatic activity of MGMT can be assessed in cell lysates from freshly resected or 
frozen tumor tissue. The main drawbacks to this approach are the potential 
contamination by non-neoplastic cells,20 and the requirement for rapid and standardized 
processing of the samples. By means of an assay that measured the transfer of 3H-
labeled methyl groups from the O6 position of guanine to protein in the cell extract, 
MGMT activity was shown to be increased in recurrent tumors specifically in patients 
who had received alkylating agent chemotherapy.21,22 However, such data have not 
been generated in a controlled, prospective manner and with parallel assessment of 
MGMT promoter methylation. 
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Immunohistochemistry 
The early studies that used immunofluorescence detection in malignant gliomas,6,7 as 
well as more-recent studies in progressive low-grade oligodendroglial tumors23 or newly 
diagnosed glioblastoma,9 reported that low MGMT protein levels had predictive value for 
the response to alkylating agents. The clinical value of immunohistochemical detection 
of MGMT protein in human gliomas, however, remains controversial for several 
reasions. First, MGMT assessment by immunochemical techniques has failed to 
correlate consistently with outcome.18,24 Second, a high interobserver variablility, even 
among expert neuropathologists, casts doubt on the reproducibility of this method of 
assessment.18 Third, many authors have failed to identify a correlation between MGMT 
promoter methylation assessed by MSP and protein levels in glioma tissue assessed by 
immunochemistry.18,24-26 One explanation for this lack of correlation is the considerable 
and highly variable contamination of glioma tissue sections with non-neoplastic cells 
expressing MGMT that are not always easy to distinguish from tumor cells (Figure 3). 
Furthermore, published cut-off levels employed to define low versus high MGMT 
expression are highly variable (ranging from >10% to >50% positive cells).18 The extent 
to which such variation accounts for the conflicting results remains unknown.  
 
mRNA expression 
MGMT mRNA levels can be determined in fresh surgical specimens, although 
contamination by mRNA from non-neoplastic cells makes the results difficult to interpret. 
In situ hybridization might circumvent this problem, but specific delineation of tumor 
cells, as well as careful and uniform handling of the samples to prevent degradation, 
remains a challenge, as does any effort at quantification. 
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MGMT promoter methylation 
The widespread recognition of the value of the MGMT promoter methylation status 
derives from its identification as a predictive marker for prolonged PFS and overall 
survival in temozolomide-treated patients in the EORTC–NCIC study. This study used a 
gel-based MSP assay that is now widely employed.13,27,28 
 Diagnostic methylation-specific assays aim at predicting the activity of the whole 
MGMT promoter by interrogating only a fraction of the CpGs for their methylation status. 
In other words, the test needs to predict overall dense promoter methylation that is 
associated with silencing of the gene (Figure 2a). The CpGs interrogated by different 
methylation-specific assays are depicted in Figure 2b. The principle for the 
discrimination of unmethylated from methylated sequences that is used by most 
methylation-specific assays is based on a bisulfite treatment step that converts 
unmethylated cytidine—but not 5-methylcytidine—in the DNA to uracil (Figure 4). 
Subsequent detection and quantification of the methylated and unmethylated sequences 
can be performed by various technologies to create semiquantitative or quantitative 
assays (Table 1).  
MSP is the most commonly used technology at present (Tables 2 and 3). This 
technique uses methylation-specific primers, each of which is designed to bind only to 
completely methylated or unmethylated sequences. Each primer typically interrogates a 
series of three to five CpGs.27–29 MSP can be performed using real-time PCR platforms 
that allow standardization, high-throughput analysis, and definition of cut-off points.30,31  
Other quantitative or semiquanitative methods include methylation-specific 
pyrosequencing, which interrogates between 4 and 12 CpGs,32 and methylation-specific 
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clone sequencing. Restriction enzymes that differentiate between methylated and 
unmethylated sequences are used in combined bisulfite restriction analysis (COBRA)32 
and methylation-specific multiplex ligation-dependent probe amplification (MS-MPLA).33 
The latter technique does not depend on bisulfite conversion. Recently developed 
technologies that analyze bisulfite-converted DNA include methylation-sensitive high-
resolution melting (MS-HRM; a PCR-based method that differentiates the melting 
behavior of the amplicons derived from methylated and unmethylated sequences),34 
bead array-based technologies,35 mass spectroscopy,36 and denaturing high-
performance liquid chromatography.37 
Each technology must define a cut-off point for the prognostic effect of the MGMT 
methylation status, which needs to be validated prospectively. Quantitative assays are 
more amenable to definition of technical cut-off points and quality control than are 
qualitative assays, as illustrated by qMSP.29,31 Completely quantitative or 
semiquantitative assays that normalize to a control gene or the copy number of the 
unmethylated MGMT promoter sequence might underestimate MGMT methylation, 
because contaminating nontumoral tissue will contribute to the signal of the normalizing 
gene. The tissue used for DNA isolation must, therefore, be macrodissected by the 
neuropathologist, so as to avoid infiltration zones, lymphocyte infiltrates, and regions 
dominated by vascular proliferation. Samples consisting of compact tumor tissue of 
sufficient size; for example, four paraffin sections with a compact tumor surface of 0.5x1 
cm, generally provide good results. Stereotactic biopsies should be controlled for tumor 
content, and usually only yield sufficient DNA when obtained frozen.25 Tissues should be 
fixed in buffered formalin. Overfixation decreases the quality of the DNA owing to 
formation of cross-links, and can impede successful testing. 
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Bisulfite conversion is the most critical step, since incomplete conversion yields 
an apparently ‘methylated’ CpG. The procedure should, therefore, be controlled for 
completion of the reaction.29 A number of commercial kits work reliably. Bisulfite-treated 
DNA is unstable and should be used rapidly, although storage at –20°C in aliquots will 
slow down the decay.  
To date, MSP is the only test that has repeatedly been shown to be of predictive 
or prognostic value in clinical trials (Tables 2 and 3).11,38 At present, qMSP31 is being 
used for patient selection in the CENTRIC trial (http://clinicaltrials.gov, NCT00689221). 
This trial is assessing a role for cilengitide in newly diagnosed glioblastoma in light of 
promising phase II data indicating that the activity of this drug is restricted to patients 
with MGMT promoter methylation (Stupp, R. et al., unpublished work). Furthermore, on 
the basis of a strong preclinical rationale, the activity of enzastaurin and radiotherapy in 
newly diagnosed glioblastoma is being assessed only in patients with an unmethylated 
MGMT promoter.39 The results of prospective validation of a qMSP-based test,31 in a 
randomized phase III trial of glioblastoma patients treated with temozolomide in the 
Radiotherapy Oncology Group (RTOG) 0525 EORTC Intergroup trial 
(http://clinicaltrials.gov, NCT00304031), are expected by early 2010. The quantitative 
evaluation of MGMT methylation in this trial is expected to provide a clinically relevant 
cut-off point, as opposed to the technical cut-off already defined.31 Validation of other 
technologies is awaited. Given the large variation of 30–60% MGMT methylation 
reported in the literature for glioblastoma, clinical validation of cut-offs for individual tests 
is crucial. Methylation testing performed outside the academic trial context should also 
follow a specified protocol that lends itself to independent reproduction. In the future, the 
use of prospectively validated tests should become standard. 
 13 
 
THE ROLE OF MGMT IN GLIOMA SUBTYPES 
Glioblastoma 
The MGMT promoter methylation status, as determined by MSP, is the strongest 
prognostic factor for outcome in patients with newly diagnosed glioblastoma, and is a 
powerful predictor of response to alkylating chemotherapy (Table 2).10,11,13,38,40,41 The 2 
year and 5 year survival rates in patients with a methylated MGMT promoter treated with 
concomitant and adjuvant temozolomide were 49% and 14%, respectively, while the 
corresponding figures for patients initially treated with radiotherapy only were 24% and 
5%. Of patients with an unmethylated MGMT promoter, 15% and 8% were alive at 2 
years and 5 years, respectively, after treatment with combined chemoradiotherapy, 
compared with 2% and 0% in those initially treated with radiotherapy alone.42 The small 
improvement in outcome even in the patients with an unmethylated MGMT promoter 
could be attributable to the above-mentioned gray zone separating methylated and 
unmethylated tumors, and the consequent somewhat arbitrary separation into two 
groups. Incorrect test results, misdiagnosis of some lower grade gliomas, differences in 
post-progression therapy, and individual variability due to other, as yet unrecognized, 
prognostic factors could also explain the marginally improved outcome of combined-
modality treatment in patients with an unmethylated MGMT promoter.  
The prognostic relevance of MGMT promoter status has been confirmed in elderly 
glioblastoma patients treated with concomitant and adjuvant temozolomide.43 In 
addition, the observation that 74% of patients with glioblastoma who survive for >5 years 
have MGMT promoter methylation—as opposed to <50% in an unselected population of 
glioblastoma patients—also underlines the prognostic value of MGMT status.44 
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Nevertheless, long-term survival can be observed even in the absence of MGMT 
promoter methylation, indicating that MGMT promoter methylation is only one aspect of 
a very complex biological system.44,45  
A study published this year proposed that the extent of MGMT methylation, as 
measured by pyrosequencing, is a prognostic factor in glioblastoma patients treated with 
temozolomide and radiotherapy.46 Patients with >29% MGMT methylation over the 12 
CpG sites measured had a significantly better outcome than patients with >9% but ≤ 
29% methylation, a clinically interesting finding that will need prospective validation. The 
authors defined 9% methylation as the cut-off point for determining outcomes between 
methylated and unmethylated tumors [Au: OK?; yes]. This cut-off for methylation was 
considered to be statistically different from the background determined in non-neoplastic 
brain. Leaving aside the possibility that methylation detected at a low level could reflect 
a false-positive result, a low methylation average could, in some cases, signify the 
presence of only a few methylated CpGs, as suggested by the unsupervised analysis of 
the MGMT methylation pattern used in this study. Such low positive scores might not 
necessarily reflect the dense methylation that is required for silencing of the gene. In 
comparison, MSP would only recognize dense methylation and would not detect small 
numbers of methylated CpGs, highlighting the different information content of the results 
rendered by these two technologies.  
In contrast to newly diagnosed glioblastoma, the predictive value of MGMT 
promoter methylation has remained controversial in recurrent glioblastoma. The 
absence of a strong predictive effect on tumor response or outcome with various 
temozolomide administration schedules47–49 suggests that MGMT-independent 
mechanisms of resistance have a predominant role in the setting of recurrent 
Gelöscht: , a clinically 
interesting finding that will need 
prospective validation
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glioblastoma. Nevertheless, patients with MGMT-methylated tumors still showed 
improved survival in these series, although no such effect was seen in a recent study 
from Belgium.50 Selection for loss of mismatch repair proteins, such as MSH6, could be 
involved in a minority of patients.51–53 In vivo evidence for the direct involvement of 
MGMT in the response of glioblastoma to alkylating agents has been provided by The 
Cancer Genome Atlas.54 Mutation analyses of 601 genes in 91 matched tumor and 
normal samples identified a hypermutator phenotype in the recurrent glioblastoma of a 
subset of 7 of 19 patients pretreated with alkylating agents. This phenotype was much 
more common in tumors with a methylated MGMT promoter (6 of 6 MGMT-methylated 
cases) than those with an unmethylated promoter. Moreover, in all 6 treated and MGMT-
methylated glioblastomas that were hypermutated, at least one of the mismatch repair 
genes MLH1, MSH2, MSH6 and PMS2 was mutated, compared with only 1 of 84 non-
hypermutated, untreated glioblastomas. The gene mutation pattern, including mutations 
of the mismatch repair genes, was different in the six patients whose glioblastoma 
carried a methylated MGMT promoter from the pattern seen in unmethylated and treated 
tumors (n=13). This discovery was compatible with a deficiency in repair of alkylated 
guanine residues, as reflected in a strong predominance of G:C to A:T transitions at 
non-CpG sites (146/181 [81%] mutations in the 6 treated, MGMT-methylated patients 
versus 29/99 [29%] in the 13 treated, MGMT-unmethylated patients). These findings are 
consistent with escape from MGMT methylation-mediated sensitivity to the alkylating 
drug by selection for mismatch repair deficiency.  
The value of temozolomide in the setting of recurrent glioblastoma, including its 
relationship with MGMT promoter methylation status, must now to be determined in 
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patients who have already been exposed to temozolomide in the first-line setting,55,56 as 
is being pursued in the DIRECTOR trial (http://clinicaltrials.gov, NCT00941460).  
 
Anaplastic glioma 
The NOA-04 trial showed no difference in PFS or overall survival between patients with 
anaplastic glioma started on radiotherapy alone and patients started on temozolomide or 
PCV alone. Interestingly, MGMT promoter methylation predicted prolonged PFS 
irrespective of the initial treatment.14 Similar results were obtained in the EORTC trial 
26951, in that MGMT promoter methylation was prognostic for PFS in both arms—
radiotherapy alone and radiotherapy followed by PCV.15 The high correlation of MGMT 
promoter methylation with the 1p19q co-deletion15,57,58 and isocitrate dehydrogenase 
(IDH) gene mutations,59 which are known to be favorable prognostic factors in anaplastic 
glioma,14,60,61 might indicate that epigenetic deregulation of MGMT occurs in a specific 
pathogenetic context in anaplastic gliomas. Since MGMT promoter methylation is 
prognostic and not predictive for chemotherapy response in anaplastic gliomas, a 
methylated MGMT promoter should not be used to justify the upfront treatment of these 
tumors with temozolomide-based radiochemotherapy in the absence of appropriate data 
from studies such as CATNON (http://clinicaltrials.gov, NCT00626990). 
 
Low-grade glioma 
An initial study on 49 patients reported that MGMT promoter methylation is a negative 
prognostic factor for PFS in patients with low-grade astrocytomas.62 The population was, 
however, mixed, in that approximately one-quarter of the patients were untreated after 
surgery, one-quarter received radiotherapy, and half received interferon only. By 
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contrast, protracted treatment with temozolomide in a phase II study in low-grade glioma 
showed improved outcome in patients with MGMT promoter methylation.63 One might 
speculate that the differences in outcome attributed to the MGMT status were, in fact, 
due to the alkylating agent therapy that was present in the latter study. Both MGMT 
promoter methylation64 and low MGMT protein levels23 were reported to predict a 
favorable response to temozolomide in low-grade oligodendrogliomas. In addition, a 
correlation exists between MGMT promoter methylation and the 1p19q co-deletion and 
mutations of the IDH1 gene in these tumors,57,59 as well as in anaplastic gliomas14,59 
(see above). Which of these changes, or other aberrations yet to be identified, contribute 
most to the chemosensitivity of these tumors remains to be elucidated. 
 
Pseudoprogression, relapse patterns and MGMT 
The idea that MGMT methylation status might have clinical relevance was supported by 
the analysis of peculiar false-positive neuroradiological patterns mimicking early disease 
progression in patients after radiochemotherapy involving temozolomide. These 
patterns, termed ‘pseudoprogression’, are usually seen in the first 3 months after 
completion of radiotherapy with concomitant chemotherapy, and may be more common 
in patients with MGMT-methylated tumors, possibly signifying the extent of cytotoxic 
effects of treatment.65  
Some have speculated that the increase in overall survival observed in patients 
with glioma treated with temozolomide concomitant with radiotherapy could be 
associated with altered patterns of relapses. For many years, relapse inside the 
radiotherapy field in 90% of all cases has been the rule for patients with glioblastoma. A 
recent analysis of the EORTC 26981–22981-NCIC CE.3 trial showed a frequency for 
Gelöscht:  status [Au: OK? 
Level 2 subheadings can be 
no longer than 45 characters, 
including spaces]
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distant recurrences of 20%.66 This analysis, which was carried out using a novel 
observer-independent tool, demonstrated no differences in the recurrence pattern 
(distant versus local) according to either therapy or MGMT status. In another series, 
MGMT promoter methylation was associated with an increased frequency of distant 
recurrences, defined as recurrences with ≤20% enhancing tumor residing inside the 
95% isodose of the radiation field.67 The best methodology to determine this clinically 
relevant point needs to be confirmed prospectively.  
 
A ROLE FOR ROUTINE MGMT TESTING?  
MGMT promoter methylation is now recognized to be a relatively early molecular lesion 
in the pathogenesis of gliomas. The frequencies of methylation seem to be specific to 
the glioma subtype and malignancy grade, as depicted in Figure 5. Whether a 
methylated MGMT promoter has the same relevance in all types of gliomas and for all 
grades of malignancy, however, remains a matter for debate. In glioblastoma, for 
example, in contrast to all other glioma subtypes, one MGMT allele is frequently lost by 
deletion of one copy of chromosome 10. Loss of one allele plus methylation is likely to 
have more profound effects on MGMT expression than methylation alone.   
The true value of MGMT promoter methylation as a diagnostic and prognostic 
marker suitable for treatment decisions depends in part on the answers to several 
crucial questions. First, which area of the gene is most relevant for silencing through 
methylation? Second, how do we set the clinically relevant cut-off point in quantitative 
assays? Third, how homogeneous is the MGMT promoter methylation pattern within a 
given tumor? Last, how stable is the methylation pattern throughout the course of 
disease and on disease progression? Importantly, at present we have no appropriate 
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alternative treatments for patients whose MGMT promoter methylation profile does not 
suggest a substantial benefit from alkylating agent chemotherapy. Withholding such 
treatment on the basis of this profile, therefore, would seem to be inappropriate at this 
stage.  
A thorough analysis of two to four biopsy specimens from each of 25 WHO grade 
III or IV gliomas revealed that MGMT promoter methylation is a highly homogeneous 
marker in malignant gliomas. MSP and sodium bisulfate sequencing showed identical 
results, and only one tumor showed inconsistent results between biopsies.25 
Little is known regarding therapy-induced changes in MGMT promoter 
methylation or MGMT expression levels in the tumor. Neither dexamethsone nor 
irradiation induced MGMT gene transcription in glioma cells in vitro.68 In tissue culture 
and animal studies, however, temozolomide strongly induced MGMT protein expression 
in temozolomide-resistant glioma cells lacking MGMT promoter methylation.69 
Loss of MGMT promoter methylation might represent a key mechanism by which 
patients with initially methylated tumors eventually acquire resistance to temozolomide, 
leading to progression or relapse. Data on changes in methylation status, however, 
remain scarce. A study of 14 patients with initial low-grade astrocytoma histology 
showed that three patients acquired methylation at recurrence, but no initially methylated 
tumor lost its methylation.62 Another small study reported changes in methylation status 
in three of ten patients, but a possible relationship with treatment was not explored.70 Of 
ten patients treated with temozolomide chemoradiation in phase II or III trials,11,13 eight 
tumors remained unchanged (one unmethylated and seven methylated), while one 
gained and another lost MGMT promoter methylation (Hegi, M. E. unpublished work). 
Similarly, an analysis of paired primary and recurrent glioblastoma tissue samples from 
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patients initially treated with radiotherapy and temozolomide by the German Glioma 
Network indicated that the MGMT promoter methylation status remained stable in the 
vast majority of patients (Reifenberger, G. and Weller, M., unpublished work). Hence, 
treatment resistance seems not to be associated with changes in the MGMT methylation 
status.  
 Taken together, the data summarized so far indicate that the determination of 
MGMT promoter methylation undoubtedly yields prognostic information, but is rarely 
useful for clinical decision-making in individual patients. Could MGMT testing have a role 
in clinical trials for patients with glioma? Several current trial concepts use the MGMT 
status, as determined by MSP, for stratification or as an inclusion criterion, limiting 
enrollment to patients either with methylated or unmethylated tumors. Moreover, in 
Europe at least, withholding temozolomide from patients with newly diagnosed 
glioblastoma without MGMT promoter methylation is considered to be justified in the 
context of clinical trials to test the effect of a new compound. Indeed, such an approach 
is being used in a current phase II study led by the EORTC, comparing radiotherapy 
plus temsirolimus versus radiotherapy plus temozolomide. This is view is not, however, 
shared by most neuro-oncologists in the US. 
 
MGMT-DEPLETING STRATEGIES 
The presence of MGMT as a key DNA repair protein is an undisputed mechanism of 
resistance to chemotherapy with alkylating agents. Strategies to overcome MGMT-
mediated resistance have been and are being pursued. MGMT-depleting agents, such 
as O6-benzylguanine (O6-BG), act as a pseudosubstrate for MGMT, which in turn is 
consumed and subsequently targeted for proteasomal degradation. Thus, de novo 
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synthesis of MGMT is required to maintain DNA repair. Systemic application of O6-BG 
was shown to decrease MGMT activity in glioma tissue when assessed 6 hours later, 
but was no longer effective at 18 hours,71 suggesting that MGMT is rapidly 
resynthesized in vivo. Accordingly, multiple daily dosing would be necessary to maintain 
low MGMT activity. Furthermore, O6-BG depletes MGMT nonselectively, resulting in 
substantial systemic toxicity, most notably dose-limiting myelosuppression, which 
necessitates substantial dose reductions for nitrosoureas or temozolomide. The clinical 
experience has, therefore, been disappointing overall in recurrent glioblastoma, although 
some responses (16% [5/32]) were reported in patients with anaplastic glioma.72 The 
feasibility of administering O6-BG locally into the tumor cavity via an Ommaya reservoir, 
in combination with systemic temozolomide, has been explored in a single patient.73  
With the aim of increasing the dose-limiting tolerance of the bone marrow towards 
alkylating chemotherapy or inducing long-term selection of genetically modified 
hematopoietic stem and precursor cells (HSCs), HSCs were transduced with a retroviral 
vector that expresses the Pro140Lys mutant of MGMT (MGMT*), which confers 
resistance to inhibition by O6-BG. Rhesus macaque experiments with CD34+ HSCs 
demonstrated the feasibility of generating long-term repopulating MGMT* HSCs. O6-BG 
plus temozolomide or BCNU treatment provided chemoprotection of progenitor cells but 
no selection of long-term repopulating HSCs.74 A phase I clinical trial of this approach for 
patients with newly diagnosed glioblastoma or grade III astrocytoma was opened in 
2006 (http://clinicaltrials.gov, NCT00272870), but was suspended owing to low 
recruitment levels and drug availability. 
Since temozolomide is itself a substrate for MGMT, alternative, more-protracted 
dosing regimes of temozolomide have been explored in first-line and recurrent 
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glioblastoma settings. The RTOG–0525–EORTC Intergroup trial has set out to 
determine whether alternative dosing of temozolomide in the adjuvant phase after 
completion of the concomitant treatment phase, using a 3 weeks on–1 week off 
schedule, could overcome resistance to chemotherapy in the nonmethylated population 
in the first-line setting. Even if this trial proves to be positive for patients without MGMT 
methylation, the question of whether the success depended on a dose-intense 
temozolomide-dependent depletion of MGMT levels in the tumor cells still remains open. 
Two small phase II trials aiming at improving PFS and overall survival by intensifying 
alkylating agent treatments have resulted in clinical benefits only for patients with MGMT 
promoter methylation.38,75,76 The use of dose-intense temozolomide in patients with 
recurrent disease resulted in PFS rates at 6 months of 30–45%,47,48,55 suggesting 
superiority over conventional dosing using the 5 out of 28 days schedule (21%).77 
Notably, none of these studies have been able to demonstrate that the presumed 
superiority of dose-intense temozolomide regimens is truly mediated by MGMT 
depletion, because serial biopsies of brain tumors are ethically not feasible. Moreover, 
preliminary results of the UK Medical Research Council BR12 trial, which allocated 
patients with recurrent anaplastic astrocytoma or glioblastoma randomly, in a 
noncomparative design, to temozolomide for 5 out of 28 days or 21 out of 28 days, 
indicated an inferior outcome with the continuous adminstration schedule. 
 
CONCLUSIONS 
MGMT promoter methylation has emerged as an important molecular marker in patients 
with gliomas. Furthermore, the EORTC–NCIC trial has suggested that MGMT promoter 
methylation is not only a prognostic marker, but is also a predictive marker for response 
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to temozolomide in patients with newly diagnosed glioblastoma.13 Emerging data 
indicate that MGMT promoter methylation has strong prognostic relevance following 
therapy with both radiation therapy and alkylating chemotherapy in patients with 
anaplastic glioma.14,42 In this setting, MGMT promoter methylation is likely to be 
indicative of a broader molecular phenotype with prognostic significance. Correlative 
analysis with other prognostic molecular markers, such as the 1p19q co-deletion or 
IDH1 and IDH2 mutations, should further clarify the importance of MGMT promoter 
methylation in this patient population. In anticipation of the results of ongoing 
prospective phase III trials incorporating MGMT promoter methylation status, and 
validation of a diagnostic assay, treatment decisions should not yet be based on MGMT 
promoter methylation status outside clinical trials. However, all investigators conducting 
ongoing and future clinical trials in patients with glioma should consider assessing 
MGMT promoter methylation status, and probably including this factor as a stratification 
parameter. 
 
Review criteria  
The reference database MEDLINE served as the basis for the present Review. A 
literature search was performed for papers published in the English language up to 
August 2009. The keywords used were as follows: “glioma”, “MGMT”, “methylation”, 
“trial”, “alkylating agent”, “DNA repair”, and combinations thereof. The papers identified 
by this search were reviewed, as were references cited therein. The database available 
at http://clinicaltrials.gov—a registry of federally and privately supported clinical trials 
conducted in the US and around the world—was consulted for information on clinical 
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trials using the following keywords: “glioma”, “MGMT”, “methylation”, “temozolomide” 
and “alkylating agent”. 
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Figure legends 
 
Figure 1 | Map of the CpG island region of the MGMT promoter.16 a | Genomic map of 
the MGMT 5’ region. A bent arrow indicates the transcription initiation site. Binding sites 
for the Sp1 transcription factor are indicated. The CpG island (bps –552 to +289), which 
includes 97 CpG sites, is numbered from 5’ to 3’, and an outline of CpG density is 
shown. Adapted by permission from Macmillan Publishers Ltd: Nakagawachi, T. et al. 
Oncogene 22, 8835–8844 © 2003.  
 
Figure 2 | Methylation of the CpG island region of the MGMT promoter. a | Detailed 
methylation status of the whole CpG island in MGMT-expressing and MGMT-
nonexpressing cell lines. Each circle graph represents the percentage of methylated 
clones (number of methylated clones/10 analyzed clones x 100) at one of the numbered 
CpG sites. b | Visualization of CpGs interrogated by diverse methylation-specific assays. 
Alike colors signify CpGs evaluated on the same fragment, except for qMSP2 where the 
methylation-specific probe is marked in light blue and recognizes the same molecule. 
Abbreviations: COBRA, combined bisulfite restriction analysis;32 HRM, high-resolution 
melting; MGMT, O6-methylguanine-DNA methyltransferase;34 MS-MPLA methylation-
specific multiplex ligation-dependent probe amplification;33 MSP, methylation-specific 
PCR;13,28 qMSP1, quantitative MSP using methylation-specific primers;31 qMSP2, 
MethyLight—including, in addition, a methylation specific probe;29 PyroSeq, methylation 
specific pyrosequencing.32 Part a adapted by permission from Macmillan Publishers Ltd: 
Nakagawachi, T. et al. Oncogene 22, 8835–8844 © 2003. 
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Figure 3 | Immunochemical staining for MGMT protein expression in glioblastomas. a | 
Lack of nuclear MGMT expression in tumor cells from a glioblastoma with MGMT 
promoter methylation. Note staining of proliferating microvascular cells as an internal 
control. b | Strong MGMT positivity in tumor and vascular cells in a MGMT-unmethylated 
glioblastoma. c | Numerous MGMT-positive cells in a glioblastoma with MGMT promoter 
methylation. d | Staining of the same tumor for CD45 reveals prominent contamination of 
the tumor tissue with CD45+ microglial cells and macrophages, which express MGMT 
and might be responsible for erroneously positive estimates of MGMT expression and 
activity levels. The insert in part d shows double staining of perivascular macrophages 
for CD68 (red) and MGMT (brown) in another case of glioblastoma. All sections are 
counterstained with hemalum. Original microscopic magnifications were x 400 (parts a 
and b, and insert in d) or x 100 (parts c and d). Abbreviations: MGMT, O6-
methylguanine-DNA methyltransferase; v, blood vessel. 
 
Figure 4 | Bisulfite conversion of tumor DNA. Treatment of DNA with bisulfite results in 
the conversion of unmethylated cytidine into uracil, which is replaced by thymidine in the 
subsequent PCR step. By contrast, 5-methylcytidine (mC) will not be converted and thus 
remains as a cytidine. Incomplete bisulfite conversion of unmethylated cytidine will be 
interpreted as methylation in the subsequent quantification step using any technology 
and will, therefore, yield a false-positive result. 
 
Figure 5 | Frequency of MGMT promoter methylation in glioma subtypes. Frequencies 
(%) of MGMT promoter methylation were taken from 25 publications evaluating 2,994 
gliomas (avoiding overlap of studies, not exhaustive). Numbers in bars represent 
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numbers of cases considered. Data were derived from the studies cited in Tables 2 and 
3 and several additional references.25,57,62,78-87 Most studies used gel-based methylation-
specific PCR. Glioblastoma shown as ‘GBM’ are not listed under PrGBM or ScGBM, 
with the exception of one population-based study. Abbreviations: AA, anaplastic 
astrocytoma; AO, anaplastic oligodendroglioma; AOA, anaplastic oligoastrocytoma; 
GBM, glioblastoma; LA, low-grade astrocytoma; O, oligodendroglioma; OA, 
oligoastocytoma; PrGBM, primary glioblastoma; ScGBM, secondary glioblastoma.  
Table 1 | Commonly used DNA methylation-specific assays 
Technology Pretreatment Number 
of CpGs 
tested 
Test properties Principle Read out Advantages Disadvantages 
MS clone 
sequencing 
Bisulfite 
conversiona 
 
Complete 
sequence 
Quantitative Converted amplified 
sequences are cloned 
into vector and 
amplified in bacteria; 
each clone is 
sequenced 
Methylation 
status at all 
CpGs for each 
individual allele 
Comprehensive No high-
throughput option 
MSP,  
gel-based 
Bisulfite 
conversion 
  
9 Qualitative Methylation-specific 
primers: amplification 
of methylated 
sequences; 
amplification of 
unmethylated 
sequences 
Gel; presence 
or absence of 
methylation  
Sensitive; 
associated with 
prediction in trials
Difficult to 
standardize 
qMSP Bisulfite 
conversion 
  
8 Quantitative MSP using real-time 
technology 
Fully 
methylated 
MGMT 
promoter 
versus -actin 
gene  
Standardized; 
high throughput; 
technical cut off 
Recognition only 
of fully 
methylated 
sequence—may 
make technique 
too restrictive  
MethyLight 
qMSP 
Bisulfite 
conversion 
 
12 Quantitative MSP using real-time 
technology plus 
methylation-specific 
probe 
Fully 
methylated 
MGMT 
promoter 
versus control 
gene  
Standardized; 
high throughput; 
technical cut off 
Recognition only 
of fully 
methylated 
sequence—may 
make technique 
too restrictive 
Pyrosequencing Bisulfite 
conversion 
  
4–12 Semiquantitative Quantification of each 
added nucleotide 
during sequencing 
Sequence; 
average (%) 
methylation 
over all CpGs 
measured  
Standardized; 
high throughput; 
internal control 
for bisulfite 
conversion 
Cut-off definition 
COBRA Bisulfite 
conversion; 
restriction 
enzymesb: 
BstUI, TaqI  
 
5 Semiquantitative Only methylated 
sequences are cut; 
fragments are 
quantified 
Percentage of 
cut sequences; 
sequencer 
(gelc) 
Specificity; 
internal control 
for bisulfite 
conversion 
Extra step; 
depends on 
restriction sites; 
cut-off definition 
MS-MPLA Restriction 
enzyme: HhaI 
(methylation 
sensitive) 
 
4 Semiquantitative Unmethylated CpG in 
recognition site 
results in restriction; 
only methylated 
sequences get 
amplified 
Average (ratio 
methylated 
versus 
unmethylated 
alleles) 
No bisulfite 
conversion; high 
throughput 
Limited to 
restriction sites; 
cut-off definition 
MS-HRM Bisulfite 
conversion 
  
18  Semiquantitative qPCR, change of 
melting curve 
depends on presence 
of methylated 
sequences 
Percentage of 
methylated 
sequences 
defined by  
standard curve
Evaluates large 
regions; 
standardized; 
high throughput 
Cut-off definition 
 
aAll unmethylated cytidines are converted to uracil, in subsequent PCR uracil is replaced by thymidine; methylated cytidines are resistant 
to conversion and remain unchanged (Figure 4). bRestriction enzymes recognize specific sequences and cut at defined positions. cOften 
used in a qualitative manner (presence versus absence). Abbreviations: COBRA, combined bisulfite restriction analysis; MGMT, O6-
methylguanine-DNA methyltransferase; MS, methylation-specific; MS-HRM, MS-high-resolution melting; MS-MPLA, MS-multiplex 
ligation-dependent probe amplification; MSP, MS PCR; qMSP, quantitative MSP.  
 34 
Table 2 | MGMT promoter methylation in human glioblastoma  
Reference MGMT 
methylation 
frequencya  
Clinical significance of MGMT promoter methylation  
Newly diagnosed glioblastoma 
Esteller et 
al. (2000)10 
41% (12/29) Prolonged overall survival in response to radiotherapy plus alkylating agent-containing 
chemotherapy 
Hegi et al. 
(2004)11 
68% (26/38) Prolonged overall survival in response to radiotherapy plus concomitant and adjuvant 
temozolomide; phase II trial 
Hegi et al. 
(2005)13 
45% 
(92/206) 
Prolonged PFS in response to radiotherapy plus concomitant and adjuvant temozolomide as 
opposed to radiotherapy alone, and prolonged overall survival; randomized phase III trial 
Herrlinger 
et al. 
(2006)38 
42% (8/19) Prolonged PFS and overall survival in response to radiotherapy plus temozolomide and lomustin; 
phase II trial 
Criniere et 
al. (2007)88 
58% 
(136/219) 
Prolonged PFS in response to radiotherapy plus nitrosourea-based chemotherapy, as opposed to 
radiotherapy alone 
Brandes et 
al. (2008)65 
35% 
(36/103) 
Prolonged overall survival in response to radiotherapy plus concomitant and adjuvant 
temozolomide; association of pseudoprogression with methylated MGMT promoter 
Wick et al. 
(2008)66 
44% (20/45) Recurrence patterns revealed no difference between groups, treatment arm or MGMT methylation 
status (radiotherapy, n=22; radiotherapy plus concomitant and adjuvant temozolomide, n=23); 
randomized phase III trial 
Brandes et 
al. (2009)67 
34% (32/95) Pattern of and time to recurrence strictly correlated with MGMT methylation status in patients 
treated with radiotherapy plus concomitant and adjuvant temozolomide 
Brandes et 
al. (2009)43 
43% (16/37) Prolonged PFS in response to radiotherapy plus concomitant and adjuvant temozolomide and 
prolonged overall survival in elderly patients 
Zawlik et al. 
(2009)89 
44% 
(165/371) 
No prognostic effect in patients treated without chemotherapy (surgery, n=105; maximal surgery 
plus radiotherapy, n=208; radiotherapy alone, n=10; supportive care only, n=29)  
Dunn et al. 
(2009)46 
53% 
(58/109) 
Prolonged PFS and overall survival in response to radiotherapy plus concomitant and adjuvant 
temozolomide; extent of MGMT methylation associated with outcome 
Prados et 
al. (2009)90 
36% (16/44) Prolonged overall survival in response to radiotherapy plus concomitant and adjuvant 
temozolomide plus erlotinib; phase II trial 
Weller et al. 
(2009)40 
44% 
(133/295) 
Prolonged PFS and overall survival in response to radiotherapy plus concomitant and adjuvant 
temozolomide; prospective collection 
Weiler et al. 
(2009)76 
41% (16/39) Prolonged PFS in response to radiotherapy plus concomitant and adjuvant (1 week on–1 week off) 
temozolomide plus indomethacin; phase II trial 
Clarke et al. 
(2009)91 
19% (9/48) No difference of PFS or overall survival in response to radiotherapy plus concomitant and dose-
modified adjuvant (1 week on–1 week off versus continuous) temozolomide 
Recurrent glioblastoma  
Brandes et 
al. (2006)47 
46% (10/22) No prognostic significance in recurrent disease treated with temozolomide (3 weeks on–1 week off) 
Wick et al. 
(2007)48 
47% (17/36) No prognostic significance in recurrent disease treated with temozolomide (1 week on–1 week off) 
Brandes et 
al. (2009)49 
34% (13/38) 
at first 
surgery; 
29% (11/38) 
at second 
surgery  
No prognostic value of MGMT promoter methylation at recurrence in patients pretreated with 
radiotherapy plus adjuvant or concomitant and adjuvant temozolomide 
aMGMT promoter methylation analysis performed by gel-based methylation-specific PCR, except the study by Dunn et al. 
(pyrosequencing).46 Abbreviations: MGMT, O6-methylguanine-DNA methyltransferase; PFS, progression-free survival.  
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Table 3 | MGMT promoter methylation in various human gliomas 
Reference MGMT 
methylation 
frequencya  
Clinical significance of MGMT promoter methylation  
Anaplastic astrocytoma 
Wick et al. 
(2009)14 
50% (48/96) Prolonged PFS and overall survival in response to radiotherapy or chemotherapy with 
temozolomide (5/28 [Au: OK for all? YES]) or PCV; phase III trial 
Anaplastic oligoastrocytoma 
Brandes et 
al. (2006)92 
69% (37/54) No prognostic significance in recurrent oligoastrocytoma or oligodendroglioma treated with 
temozolomide (5/28) 
Wick et al. 
(2009)14 
71% (53/75) Prolonged PFS and overall survival in response to radiotherapy or chemotherapy with 
temozolomide (5/28) or PCV; phase III trial 
Anaplastic oligodendroglioma 
Wick et al. 
(2009)14 
71% (22/31) Prolonged PFS and overall survival in response to radiotherapy or chemotherapy with 
temozolomide (5/28) or PCV; phase III trial 
Anaplastic oligodendroglioma and anaplastic oligoastrocytoma without necrosis 
van den 
Bent et al. 
(2009)15 
84% (81/97) Prolonged PFS and overall survival in response to radiotherapy or chemotherapy with PCV; phase 
III trial 
Anaplastic oligoastrocytoma with necrosis (glioblastoma) 
van den 
Bent et al. 
(2009)15 
73% (29/40) No prolonged PFS and overall survival in response to radiotherapy or chemotherapy with PCV; 
phase III trial 
Recurrent anaplastic astrocytoma or oligoastrocytoma and glioblastoma 
Sadones et 
al. 200950 
26% (10/38) Prolonged overall survival in response to temozolomide (5/28 or 1 week–1 week off) in anaplastic 
astrocytoma and oligoastrocytoma 
Grade II astrocytoma  
Komine et 
al. 200362 
43% (21/49) Decreased PFS with no treatment or radiotherapy or interferon 
Grade II oligodendroglioma and oligoastrocytoma  
Everhard et 
al. 200664 
93% (63/68) Prolonged PFS in patients with oligodendroglioma (n=42), oligoastrocytoma (n=18) or astrocytoma 
(n=8) treated with temozolomide 
Kesari et al. 60% (12/20) Prolonged PFS and OS in patients treated with temozolomide (11 weeks on–4 weeks off); phase II 
trial 
aMGMT promoter methylation analysis performed by gel-based methylation-specific PCR, except studies by Sadones et al. 
(quantitative methylation-specific PCR)50 and van den Bent et al. (methylation-specific multiplex ligation-dependent probe 
amplification.)15 Abbreviations: 5/28, 5 out of 28 days; PFS, progression-free survival; PCV, combination of procarbazine, CCNU 
(lomustine) and vincristine.
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